Drug Trial Radar · NCT07373262
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement
Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Mar 1, 2030
Study completion Jul 1, 2030
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ANCA-associated vasculitis (AAV) is a rare auto-immune disease, with high mortality in the absence of treatment. There is still an unmet need to define new treatment strategies to reduce drug side effects, as well as to reverse rare cases of refractory AAV and improve the kidney response to improve the long-term outcomes. Severe forms of AAV-related necrotizing and crescentic rapidly progressive glomerulonephritis (RPGN) (i.e. estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²) are associated with higher mortality, higher incidence of infections, and long-term consequences including chronic kidney disease (CKD) with subsequent complications (end-stage kidney disease (ESKD) requiring dialysis, cardiovascular diseases) and a burden of financial costs. In patients with AAV and RPGN, recent guidelines recommend using a standard-of-care (SOC) immunosuppressive regimen including an induction regimen (rituximab or cyclophosphamide), plus glucocorticoids (GCs) (starting at 60 mg/day and tapering over 6-12 months) (+ or - plasma exchanges). Since GCs also participate to the long-term control of AAV, new molecular pathophysiology-driven therapeutic approaches rapidly blocking and/or reversing AAV lesions are needed to go beyond the progressive control of AAV using GCs alone. Thus, an add-on approach including GCs-based immunosuppressive regimen plus a new targeted therapy may lead to both AAV control (systemic disease) and improvement of the kidney outcome (organ involvement). Avacopan a selective inhibitor of the C5a receptor, recently emerged as a new therapeutic option in AAV. In a phase 3 comparative study (that included a small subset of patients with eGFR 15-29 mL/min/1.7m2), avacopan was superior to glucocorticoids taper with respect to sustained remission at week 52. In the avacopan arm, the cumulative dose of GCs was dramatically reduced and avacopan was thus proposed as an alternative to GCs rather to a synergic treatment. In the subgroup of patients with eGFR \<30 mL/min/1.73m², avacopan was associated with a better eGFR gain at week 52 compared to prednisone, but data in this population at-risk of worse kidney outcomes are scarce, and did not include patients with eGFR \< 15 mL/min/1.73m², those patients being excluded from the study. In the REVERSE study, investigators put forward the hypothesis that avacopan added on GCs regimen may significantly improve the kidney outcome of severe AAV (synergic approach), and thus improve short- and long-term global outcomes (survival, cardiovascular status). REVERSE will thus compare GCs-based SOC + placebo to GCs-based SOC + avacopan.
Conditions
- ANCA-Associated Vasculitis (AAV)
Interventions
AvacopanDrug
At day 0, and weeks 4, 8, 12, 20 36 patients will have avacopan dispensation
PlaceboDrug
At day 0, and weeks 4, 8, 12, 20 36 patients will have placebo dispensation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in the kidney functionTime frame: Day 0 and 52 weeks after randomization
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Amiens Hospital
Amiens, France
Angers Hospital
Angers, France
Besançon Hospital
Besançon, France
Bordeaux Hospital
Bordeaux, France
Boulogne-sur-Mer Hospital
Boulogne-sur-Mer, France
Brest Hospital
Brest, France
Caen Hospital
Caen, France
Grenoble Hospital
Grenoble, France
Vendée Hospital
La Roche-sur-Yon, France
Le Mans Hospital
Le Mans, France
Lille Hospital
Lille, France
Limoges Hospital
Limoges, France
Marseille Hospital
Marseille, France
Nantes Hospital
Nantes, France
Nimes Hospital
Nîmes, France
Bichat Hospital
Paris, France
Cochin Hospital
Paris, France
George Pompidou Hospital
Paris, France
Henri Mondor Hospital
Paris, France
Kremlin Bicêtre Hospital
Paris, France
Necker Hospital
Paris, France
Tenon Hospital
Paris, France
Reims Hospital
Reims, France
ROuen Hospital
Rouen, France
Strasbourg Hospital
Strasbourg, France
Saint exupery hospital
Toulouse, France
Toulouse Hospital
Toulouse, France
Tours Hospital
Tours, France
Valenciennes Hospital
Valenciennes, France
NANCY Hospital
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.